Table 3 Association between DDR gene nutations and clinical responses to platinum-based chemotherapy and platinum-based chemotherapy/immunotherapy in advanced NSCLC patients
Platinum-based chemotherapy | ||||
|---|---|---|---|---|
Response | DDR negative | DDR positive | Odd ratio | P value |
ORR | 1.45 | 1 | ||
non-ORR | 3 | 4 | ||
ORR (CR + PR) | 2 | 4 | ||
DCR | 0 | 1 | ||
non-DCR | 0 | 1 | ||
DCR (CR + PR + SD) | 5 | 7 | ||
Platinum-based chemotherapy/immunotherapy | ||||
Response | DDR negative | DDR positive | Odd ratio | P value |
ORR | 0.47 | 0.44 | ||
non-ORR | 10 | 6 | ||
ORR (CR + PR) | 11 | 3 | ||
DCR | 0 | 0.0046 | ||
non-DCR | 0 | 4 | ||
DCR (CR + PR + SD) | 21 | 5 | ||